Lilly to invest $6 billion in Huntsville manufacturing hub

The new site will produce next-generation synthetic medicine active pharmaceutical ingredients

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy

Dhoni joins Arth by Emcure to tackle iron deficiency on World Iron Deficiency Day

Eli Lilly to spotlight groundbreaking BTK inhibitor Jaypirca at ASH 2025

Jaypirca is making waves in the fight against B-cell malignancies

FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures

Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels

India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions

According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic

Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics

The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line

Alembic announces USFDA final approval for Dasatinib Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets